-
Pfizer Ponders A Move
Thursday, July 14, 2011 - 11:14am | 55A few months ago, pharma giant Pfizer (PFE) got a boost when Sanford Bernstein analyst Tim Anderson (and a few other street colleagues) mentioned that company management was open to spinning off or selling parts of the business. This set off a flurry of reports analyzing potential castaways with...
-
Cephalon Shareholders Approve Acquisition by Teva
Thursday, July 14, 2011 - 11:06am | 81Cephalon, Inc. (Nasdaq: CEPH) today announced that its stockholders voted to approve the Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) proposal to acquire Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion. The transaction remains under review by...
-
Options Brief: Adolor
Thursday, July 14, 2011 - 10:36am | 81Shares of Adolor Corporation (NASDAQ: ADLR) are higher on the session by 8.58%, trading at $2.53. Overall call volume is now running at 461.54x the daily average, with 0% of all calls traded being purchases on the offer. 6,000 contracts have traded on the session so far. Adolor Corporation is a...
-
NASDAQ Stocks Hitting 52-Week Highs
Thursday, July 14, 2011 - 10:18am | 132Shire plc (NASDAQ: SHPGY) shares rose 1.41% to create a new 52-week high of $100.52. SHPGY's trailing-twelve-month ROE is 26.25%. Infinity Pharmaceuticals Inc (NASDAQ: INFI) shares gained 0.56% to create a new 52-week high of $9.05. INFI had $90.52 million in total cash and no debt for the latest...
-
MLV Commnets On FDA Approval For SuperGen New Drug Application
Thursday, July 14, 2011 - 9:05am | 120According to MLV, SuperGen (NASDAQ: SUPG) and its U.S. collaborative partner Eisai announced that the FDA has accepted the supplemental New Drug Application (sNDA) of Dacogen for the treatment of acute myeloid leukemia. MLV said that it expects the FDA to assign a PDUFA date of next March, 2012,...
-
Piper Jaffray Initiates Jazz Pharmaceuticals At Overweight, $51 PT
Thursday, July 14, 2011 - 6:13am | 25Piper Jaffray has initiated coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with an Overweight rating and $51 price target.
-
Stocks to Watch for Thursday 7/14/2011: Fresh 52 Week Highs and Lows
Thursday, July 14, 2011 - 2:29am | 1820Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels. The following stocks hit new 52-week highs in Wednesday's trading session (listed from highest total volume to lowest): 1) SPDR Gold Shares (NYSE: GLD):...
-
Stocks Going Ex Dividend the Third Week of July
Wednesday, July 13, 2011 - 11:42pm | 834Here is our latest update on the stock trading technique called 'Buying Dividends'. This is the process of buying stocks before the ex dividend date and selling the stock shortly after the ex date at about the same price, yet still being entitled to the dividend. This technique generally works only...
-
Boston Scientific Earnings Preview: Revenue, Earnings Expected to Fall from Previous Quarter
Wednesday, July 13, 2011 - 12:44pm | 425Get ready for Boston Scientific (NYSE: BSX) earnings! Don't be the last to know: The company announces its next round of earnings this Monday, July 18, 2011. No time to prep before Monday's announcement? Don't worry. Here is your everything-that-matters guide to Boston Scientific's second quarter...
-
Options Brief: Warner Chilcott
Wednesday, July 13, 2011 - 10:38am | 78Shares of Warner Chilcott (NASDAQ: WCRX) are higher on the session by 0.04%, trading at $24.21. Overall put volume is now running at 2.98x the daily average, with 0% of all puts traded being purchases on the offer. 2,029 contracts have traded on the session so far. Warner Chilcott plc. is a...
-
Argus Initiates Coverage of Teva Pharmaceutical with Buy, $58 PT
Wednesday, July 13, 2011 - 9:57am | 32The report went out earlier this morning. Currently, Teva (NASDAQ: TEVA) is trading at $49.45 in regular market trading, a gain of 0.7% versus yesterday's close.
-
FDA Accepts DACOGEN sNDA Submission in Acute Myeloid Leukemia
Wednesday, July 13, 2011 - 8:03am | 79SuperGen, Inc. (NASDAQ: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information that the U.S. Food and Drug Administration has accepted for review its supplemental New Drug Application seeking...
-
Citi Reiterates Hold and Pt of $35 on Forest Laboratories
Wednesday, July 13, 2011 - 7:56am | 60Citi reiterated its Hold rating on Forest Laboratories (NYSE: FRX). At the same time, the rating agency left its price target on the company's stock unchanged at $35 ahead of the company's Q2 earnings report, which is due on July 19th. On Tuesday, FRX lost 0.23% of its value to finish the day at $...
-
QE3 07-12-2011
Tuesday, July 12, 2011 - 6:25pm | 859Cusick's Corner The Fed notes came out, and QE3 now looks to be on the table, which catalyzed that the market specifically getting the Euro, E7U11, over $1.40 and the Dollar, DXU11, pulled back to the 76 level. But that was short lived when Moody's downgraded Irish debt, bringing yields in the...
-
Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
Tuesday, July 12, 2011 - 4:07pm | 149Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results from Phase 2b trials in rheumatoid arthritis and ankylosing spondylitis with sarilumab (REGN88/SAR153191), a novel, high-affinity, subcutaneously administered, fully-human antibody targeting the...